8-K: Invivyd Q3 Revenue Jumps 41%, Advances COVID Antibody VYD2311

Invivyd, Inc. reported a 41% year-over-year increase in Q3 2025 PEMGARDA net product revenue to $13.1 million and received U.S. FDA IND clearance for its pivotal VYD2311 COVID prevention program.

Summary

• PEMGARDA (pemivibart) net product revenue for Q3 2025 was $13.1 million, representing 41% growth year-over-year and 11% growth quarter-over-quarter.
• Cash and cash equivalents exceeded $100 million as of October 2025, with $85.0 million reported at the end of Q3 2025.
• The company closed a $57.5 million public offering in August 2025 and generated an additional $29.8 million gross proceeds from an at-the-market (ATM) offering facility in October 2025.
• U.S. FDA IND clearance was announced in October 2025 for VYD2311, a vaccine-alternative antibody to prevent COVID, with alignment on its pivotal clinical program.
• The REVOLUTION clinical program for VYD2311, comprising DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID vaccination) clinical trials, is expected to begin around year-end 2025, with top-line data anticipated mid-2026.
• Net loss for Q3 2025 significantly decreased to $10.5 million, compared to $60.7 million for the comparable period in 2024.
• Research & Development (R&D) expenses were $8.0 million for Q3 2025, a substantial decrease from $57.9 million in Q3 2024.
• Selling, General & Administrative (SG&A) expenses increased to $15.0 million for Q3 2025, up from $13.0 million in Q3 2024.
• Invivyd initiated discovery efforts to expand its pipeline beyond SARS-CoV-2, including potential targets such as respiratory syncytial virus (RSV) and measles.
• Paul B. Bolno, M.D., was appointed to the Board of Directors, and Kristie Kuhl was appointed as Chief Communications Officer in September 2025.

Sentiment

Score: 8

Explanation: The filing reports strong revenue growth for PEMGARDA, a significant reduction in net loss, and a strengthened cash position. Crucially, it announces FDA IND clearance for the pivotal VYD2311 program, marking a major step forward for a potential blockbuster product. The strategic focus on a vaccine alternative and pipeline expansion are also positive indicators, despite ongoing net losses and increased SG&A.

Positives

• PEMGARDA net product revenue grew 41% year-over-year to $13.1 million in Q3 2025, demonstrating strong market uptake.
• Quarter-over-quarter PEMGARDA revenue growth of 11% from Q2 2025 to Q3 2025 indicates sustained commercial momentum.
• The company's cash position strengthened to over $100 million as of October 2025, providing a robust financial runway for future operations and clinical development.
• U.S. FDA IND clearance and alignment for the pivotal VYD2311 clinical program (REVOLUTION) is a significant regulatory milestone, paving the way for advanced clinical trials.
• Net loss for Q3 2025 dramatically decreased to $10.5 million from $60.7 million in Q3 2024, reflecting improved financial performance and cost management.
• Research & Development expenses saw a substantial reduction to $8.0 million in Q3 2025 from $57.9 million in Q3 2024, indicating efficient resource allocation or completion of certain costly trial phases.
• Positive in vitro neutralization data for PEMGARDA and VYD2311 against the XFG variant of SARS-CoV-2 confirms continued efficacy against dominant variants.
• Expansion of pipeline discovery efforts beyond COVID-19 to include RSV and measles signals strategic growth and diversification.
• The company has built a strong commercial foundation for PEMGARDA, with growing uptake among healthcare providers and an expanded field presence.

Negatives

• Selling, General & Administrative (SG&A) expenses increased to $15.0 million in Q3 2025 from $13.0 million in Q3 2024, primarily due to higher personnel-related costs.
• The company continues to operate at a net loss, despite significant improvements.
• PEMGARDA is currently authorized under an Emergency Use Authorization (EUA), which carries inherent limitations and the risk of revocation or revision by the FDA.

Risks

• Uncertainties regarding future costs, expenses, revenue, capital requirements, and the availability of and need for additional financing.
• Whether the company's cash and cash equivalents are sufficient to support its operating plan for as long as anticipated.
• Uncertainties regarding market acceptance, payor coverage and reimbursement, or future revenue generated by PEMGARDA.
• How long the EUA granted by the FDA for PEMGARDA will remain in effect and whether such EUA is revised or revoked by the FDA.
• The ability to maintain a continued acceptable safety, tolerability, and efficacy profile of any product candidate following regulatory authorization or approval.
• The success of the company's in-house sales force, and its ability to maintain and expand sales, marketing, and distribution capabilities to successfully commercialize any authorized or approved product candidates.
• Changes in expected or existing competition and changes in the regulatory environment.
• Uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways.
• The timing, progress, and results of the company's discovery, preclinical, and clinical development activities, including the initiation of the DECLARATION clinical trial, and finalization and initiation of other aspects of the REVOLUTION clinical program, such as the LIBERTY clinical trial, subject to final alignment with the FDA.
• Clinical trial site activation or enrollment rates.
• Unexpected safety or efficacy data observed during preclinical studies or clinical trials.
• The predictability of clinical success of the company's product candidates based on neutralizing activity in nonclinical studies.
• The risk that results of nonclinical studies or clinical trials may not be predictive of future results, and interim data are subject to further analysis.
• The company's ability to generate the data needed to support a potential Biologics License Application (BLA) submission for VYD2311.
• Potential variability in neutralizing activity of product candidates tested in different assays.
• Variability of results in models and methods used to predict activity against SARS-CoV-2 variants.
• Whether the epitopes that pemivibart and VYD2311 target remain structurally intact.
• Whether the company's product candidates are able to demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants, particularly in the face of viral evolution.
• The company's reliance on third parties.
• Complexities of manufacturing mAb therapies, and availability of quantities of commercial product in the future, if authorized or approved.
• Macroeconomic and political uncertainties.
• The company's ability to continue as a going concern.
• Whether the company has adequate funding to meet future operating expenses and capital expenditure requirements.

Future Outlook

The company is well-poised to provide Americans with antibody protection as an alternative to COVID vaccination, preparing for pivotal studies and potential commercial launch of VYD2311 with urgency. They anticipate top-line data for the REVOLUTION clinical program by mid-2026 and are exploring pipeline expansion beyond SARS-CoV-2 to include targets like RSV and measles. They expect to invest further in VYD2311, including the REVOLUTION pivotal clinical program and execution of a go-to-market strategy and commercial build-out.

Management Comments

• "With a strengthened balance sheet and a clear path forward for VYD2311 with recent IND clearance and U.S. Food and Drug Administration (FDA) alignment, Invivyd is well-poised to provide Americans with antibody protection as an alternative to COVID vaccination." Marc Elia, Chairman of the Board of Directors.
• "Given the current unmet need, we are preparing for our pivotal studies and potential commercial launch of VYD2311 with urgency and to secure Invivyd's place as the leader in providing antibodies to prevent people from becoming sick with COVID." Marc Elia.
• "We are also looking at pathogens beyond COVID because humankind may benefit from additional, high quality immune power in preventing these illnesses." Marc Elia.
• "We are pleased that third quarter revenue growth, combined with controlled operating expenses, has set us up to invest at the appropriate level for our future growth." Bill Duke, Chief Financial Officer.
• "Our past discipline and learnings from our commercial organization will enable us to further invest in VYD2311, including upcoming initiation of our REVOLUTION pivotal clinical program and execution of a go-to-market strategy and related commercial build-out to prepare for launch, if approved." Bill Duke.

Industry Context

Invivyd is positioning itself as a leader in providing antibody protection as an alternative to COVID vaccination, addressing an unmet need for immunocompromised patients and potentially a broader market. The company highlights limitations of current mRNA vaccines (reactogenicity, myocarditis risk, short duration, modest efficacy) and positions its mAbs (VYD2311) as offering natural, supplemental, long-duration, high-efficacy, vaccine-free protection. This strategy aims to disrupt the existing COVID prevention landscape, which is dominated by vaccines, by offering a different mechanism of action and potentially better safety/durability profile for certain populations. The expansion into RSV and measles indicates a broader strategy in infectious disease prevention.

Comparison to Industry Standards

• VYD2311 is positioned as a vaccine alternative, contrasting with mRNA COVID vaccines (e.g., COMIRNATY, SPIKEVAX) which have approximately annual utilization and ~2 months of efficacy follow-up in Phase 3 RCTs.
• The company highlights mRNA COVID vaccines' potential for high discomfort and side effects (e.g., myocarditis risk) compared to expected low discomfort and low likelihood of side effects for Invivyd's COVID IM antibodies.
• The filing notes that the 2023-2024 flu season saw 147 million flu vaccine doses, with 34.2 million people receiving a flu shot but not a COVID shot, and 100-112 million receiving neither, indicating a significant potential market for alternative COVID protection.
• The company cites CDC estimates for 2023-2024 vaccine efficacy (VE) reduction in hospitalization at 36% (7 days post-dose), 51% (45-56 days), 42% (60-119 days), and 15% (120-179 days), contrasting this with anticipated high efficacy for VYD2311.
• The U.S. revenue for COVID vaccines was $3.8 billion in FY24, indicating a large market that Invivyd aims to capture with VYD2311.

Management Changes

Corporate Governance

Related Party Transactions

• Accrued expenses include related-party amounts of $716 thousand as of September 30, 2025 (down from $1,274 thousand at December 31, 2024).
• Cost of product revenue includes related-party amounts of $525 thousand for Q3 2025 and $1,449 thousand for the nine months ended September 30, 2025.
• Research and development expenses include related-party amounts of $1,158 thousand for Q3 2025 and $3,426 thousand for the nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, reduced net loss, strengthened cash position, and significant progress in the VYD2311 clinical program, which could lead to future value creation. Dilution from recent public and ATM offerings.
• Patients (Immunocompromised): Continued access to PEMGARDA for pre-exposure prophylaxis of COVID-19. Potential for a new vaccine-alternative antibody (VYD2311) for broader COVID prevention.
• Healthcare Providers: Continued support from Invivyd's sales force for PEMGARDA. Anticipated new options for COVID prevention with VYD2311.
• Employees: Increased personnel-related costs suggest potential growth in workforce, particularly in SG&A. New appointments in management.
• Creditors: Strengthened cash position improves the company's financial stability.

Next Steps

• Begin DECLARATION and LIBERTY clinical trials for VYD2311 around year-end 2025.
• Finalize alignment with the FDA on the LIBERTY trial's combination design with vaccination.
• Anticipate top-line data from the REVOLUTION clinical program by mid-2026.
• Continue commercial build-out and go-to-market strategy for VYD2311, if approved.
• Continue discovery efforts for pipeline expansion beyond SARS-CoV-2, including RSV and measles.
• Assess the effects of monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome through the SPEAR Study Group.

Key Dates

Recommendation

The company has demonstrated robust revenue growth for its existing product, PEMGARDA, and significantly reduced its net loss, indicating improved operational efficiency and market penetration. The FDA's IND clearance for VYD2311's pivotal clinical program is a transformative event, positioning Invivyd to potentially launch a vaccine-alternative monoclonal antibody for COVID prevention, addressing a substantial unmet market need. The strengthened cash position from recent capital raises provides a solid runway for these critical clinical developments. While risks inherent in clinical trials and regulatory approvals remain, the progress reported suggests a strong growth trajectory and significant upside potential, making it a compelling investment opportunity for long-term investors.

Keywords

Invivyd, IVVD, PEMGARDA, pemivibart, VYD2311, COVID-19, monoclonal antibody, mAb, biopharmaceutical, FDA, IND clearance, clinical trials, REVOLUTION program, DECLARATION trial, LIBERTY trial, Q3 2025 earnings, financial results, SARS-CoV-2, immunocompromised, vaccine alternative, RSV, measles, biotech, pharmaceuticals